COVID-19 vaccine sales slumping now, but analysts optimistic about rebound later this year

When Johnson & Johnson said on Tuesday that it would not project COVID-19 vaccine sales for this year, citing a “global supply surplus” and “vaccine hesitancy,” the news sent a rumble through Wall Street that COVID vaccine sales could drop considerably this year as the world tries to shift from the pandemic to an endemic stage.